Lessons From Lyme Disease: Six Reasons The CDC’s COVID-19 Failure Was Predictable
Lessons From Lyme Disease: Six Reasons The CDC’s COVID-19 Failure Was Predictable
I don’t know why anyone continues to trust the CDC with anything.
Lyme patient and advocate Carl Tuttle tuned into the Tick-borne Disease Working Group Meeting on March 3 & 4 and listened with dismay as Chief of the Bacteriology and Mycology Branch NIAID, NIH – Dr. Dixon referenced the unscientific Klempner Trial that has been used for decades against using further treatment for Lyme/MSIDS patients with remaining symptoms.
He sent the following to Dixon: https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/25847056?
700 articles LYME Evidence of Persistence
https://www.dropbox.com/s/n09sk90eo6xz7ua/700%20articles%20LYME%20EvidenceofPersistence-V2.pdf?dl=0
The most disturbing reference for persistent infection originates from the Centers for Disease Control in Fort Collins, Colorado where Borrelia burgdorferi, was grown from the cerebrospinal fluid of Lyme patient Vicki Logan despite prior treatment with intravenous antibiotics. Her case made the front page of the New York Times Science Times in August of 1993.
Logan’s positive culture and autopsy report were forwarded to past CDC Director Brenda Fitzgerald, MD.
Letter to Brenda Fitzgerald, MD
https://www.dropbox.com/s/xaul84dqmqgbre0/Brenda%20Fitzgerald%20MD%20Director%20CDC.docx?dl=0
In contrast, the Klempner antibiotic trials found no evidence of B. burgdorferi in a total of more than 700 different blood and cerebrospinal fluid samples from 129 patients. That’s not statistically possible Dr. Dixon!
I reached out to Dr. Klempner in 2018 and of course there was no response.
Letter written by Tuttle in 2018 to Dr. Klempner:
Dr. Klempner,
I would like to call attention to the attached study recently identifying chronic Lyme disease in twelve patients from Canada.
Persistent Borrelia Infection in Patients with Ongoing Symptoms of Lyme Disease
http://www.mdpi.com/2227-9032/6/2/33
All of these patients were culture positive for infection (genital secretions, skin “Morgellons” and blood) even after multiple years on antibiotics so there was no relief from current antimicrobials. Some of these patients had taken as many as eleven different types of antibiotics.
In contrast, your 2001 antibiotic treatment study found; “no evidence of B. burgdorferi in a total of more than 700 different blood and cerebrospinal fluid samples from the 129 patients in these studies.”
Two Controlled Trials of Antibiotic Treatment in Patients with Persistent Symptoms and a History of Lyme Disease
http://www.nejm.org/doi/full/10.1056/NEJM200107123450202#article_references#t=references
Not a single positive Dr. Klempner? Doesn’t this statistically prove that your methodology was fatally flawed?
Did you culture skin and genital secretions as the Middelveen paper reports? It would appear that you conveniently stopped looking after your results supported the existing thirty year dogma; chronic Lyme does not exist.
Persistent Lyme disease is not new and has been intentionally/deceitfully suppressed for decades as described in the Vicki Logan case identified in the following letter to past CDC Director Barbara Fitzgerald:
https://www.dropbox.com/s/xaul84dqmqgbre0/Brenda%20Fitzgerald%20MD%20Director%20CDC.docx?dl=0
In 1991 B. burgdorferi had been isolated in culture from Vicki Logan’s CSF (CDC’s laboratory in Fort Collins CO.) despite prior treatment with 21 days of IV cefotaxime and 4 months of oral minocycline.
The dishonest science here in the U.S. has denied chronic Lyme which stifled research to find a curative approach. Now the rest of the world is suffering.
We have lost nearly four decades to this 21st century plague due to the racketeering scheme identified in the RICO lawsuit filed by SHRADER & ASSOCIATES, LLP against the Infectious Disease Society of America, seven IDSA Panelists and eight insurance companies. The U.S. Centers for Disease Control has aligned itself with the seven IDSA Panelists identified in this lawsuit.
https://www.courthousenews.com/wp-content/uploads/2017/11/LymeDisease.pdf
Lyme is an incurable disease when not treated immediately which is spreading across North America and deceitfully misclassified as a low-risk and non-urgent health issue. Patient experience is describing a disease that is destroying lives, ending careers, causing death and disability while leaving victims in financial ruin. Current antimicrobials are ineffective for eradicating all forms of the Borrelia spirochete.
Public outcry has been ignored for decades while the Centers for Disease Control sat on evidence that this infection was not easily treated with a one size fits all treatment approach as dictated by the Infectious Diseases Society of America.
Once again your studies were fatally flawed while supporting the controlling dogma leaving hundreds of thousands if not millions worldwide with a persistent infection and absolutely no relief. We have another AIDS on our hands.
Carl Tuttle
Independent Researcher
Lyme Endemic Hudson, NH
Cc: Michael F. Collins, Chancellor
____________________
**Comment**
Some of you may be wondering about the Klempner trial, which can be found here: https://www.ncbi.nlm.nih.gov/pubmed/11450676
Countering the Klempner Trial, here is a 2012 Study showing retreatment can be beneficial: https://www.sciencedirect.com/science/article/pii/S1551714412002030
Article explaining flaws in the Klempner Trial: https://www.lymedisease.org/lymepolicywonk-new-study-reveals-fatal-flaws-in-nih-klempner-trial-statistical-analysis-is-this-error-human-incompetence-or-worse/
Excerpt:
Clinical trials usually require that patients improve, but not that they return to perfect health. DeLong found that the Klempner trial set the level for determining treatment success excessively high. For instance, in the seronegative arm of the trial, treatment success required that patients not simply return to the norm for the general population, but instead surpass the norm by essentially one full standard deviation. That type of success is unheard of in clinical trials.
Many researchers say that small sample size trials are unethical because they can literally steer scientists down the wrong path. That’s what the Klempner study did. It was a waste of money, a waste of time, and it has led research down the wrong path for the last 10 years.
Second, the Klempner team could have avoided “overstating” its findings and highlighted the potential for error. The ethical implications of exaggeration in science are understood by other scientific societies. For example, the code of conduct for the American Chemical Society states: “Public comments on scientific matters should be made with care and accuracy, without unsubstantiated, exaggerated, or premature statements.”
Instead, the Klempner study concluded flatly that retreatment was ineffective.
Also, Embers et al. found Persistence of Borrelia burgdorferi in Rhesus Macaques following Antibiotic Treatment of Disseminated Infection: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0029914
For fun, I did a little sleuthing on Dr. Klempner (who is behind the new Lyme vaccine)
Klempner was optimistic. “We’ve learned some very important lessons from the LYMErix debacle, as I think some people would categorize it,” he said. “It certainly remains the only safe and effective vaccine that’s been pulled from the market.”
During LYMErix’s brief stint on the market, Clarke was among the recipients. Having had Lyme disease twice, she decided to try the vaccine. Even after receiving the final LYMErix shot, Clarke said she got Lyme disease for a third time.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906891/
We report a case of suspected Lyme neuroborreliosis (LNB) where the patient’s sole symptom was chronic, intermittent episodes of unilateral ear pain. This case was unusual because this patient did not show any other neurological or extraneurological symptoms of Lyme disease. LNB is a manifestation of infection by Borrelia burgdorferi spirochetes that can manifest in a number of different clinical presentations depending on the nervous system dissemination of the bacteria. Most commonly, these neurological findings present as peripheral nerve radiculopathies, but rarer involvement of the central nervous system (CNS) can occur if a patient goes untreated. Most often, CNS involvement presents as meningitis with increased lymphocytes but can, in rarer cases, involve the spinal cord or brain parenchyma.
The diagnosis of LNB was made after the patient was found to have suspicious lesions in the spinal cord and brain parenchyma on magnetic resonance imaging as well as cerebrospinal fluid Borrelia antibody index was consistent with CNS Lyme disease. We discuss this case as a unique clinical presentation of suspected LNB and the diagnostic findings associated with this infection.
_________________
**Comment**
Nothing surprises me about Lyme disease anymore. “Not everything is Lyme, but Lyme CAN be anything.” Truer words were never spoken.
https://www.ncbi.nlm.nih.gov/pubmed/31916316/
Proteinuria is a risk factor for progressive kidney injury in dogs. Enhanced understanding of potential associations between canine vector-borne diseases (CVBD) and proteinuria is needed.
To determine the proportion of evaluated proteinuric dogs exposed to ≥1 CVBD, including Babesia spp., Ehrlichia spp., spotted-fever group Rickettsia, Bartonella spp., Anaplasma spp., hemotropic Mycoplasma spp., Borrelia burgdorferi, and Dirofilaria immitis, and to determine if demographic or clinicopathologic differences exist between proteinuric dogs exposed to CVBD versus proteinuric dogs with no evidence of CVBD exposure.
Two-hundred nine proteinuric dogs, concurrently tested for CVBD, which were examined at a single academic veterinary hospital between January 2008 and December 2015.
Retrospective cross-sectional study. Demographic, clinicopathologic, and CVBD test results were extracted from medical records. A multivariable logistic regression model was used to assess associations between CVBD and selected variables.
Based on serology and polymerase chain reaction testing,
The CVBD exposure was lower in dogs tested in autumn or spring, higher in intact dogs, and higher in dogs with lower serum albumin and higher serum creatinine concentrations.
Exposure to CVBD, particularly exposure to Rickettsia spp., Ehrlichia spp., and B. burgdorferi was found in proteinuric dogs from the southeast United States. Additional controlled prospective studies examining a potential causal relationship between CVBD and proteinuria are warranted.
__________________
**Comment**
The question of course is – does this also happen in humans and to what degree?
https://www.ncbi.nlm.nih.gov/pubmed/32106890
Ixodes ricinus is the most common tick species in Europe and the main vector for Borrelia burgdorferi (sensu lato) and tick-borne encephalitis virus (TBEV). It is involved also in the transmission of Borrelia miyamotoi, a relapsing fever spirochete that causes health disorders in humans. Little is known regarding the circulation of Borrelia species and the natural foci of TBEV in north-eastern Germany. The goal of this study was to investigate the infection rates of Borrelia spp. and of TBEV in I. ricinus ticks from north-eastern Germany.
Ticks were collected by flagging from 14 forest sites in Mecklenburg-Western Pomerania between April and October 2018. RNA and DNA extraction was performed from individual adult ticks and from pools of 2-10 nymphs. Real time reverse transcription PCR (RT-qPCR) targeted the 3′ non-coding region of TBEV, while DNA of Borrelia spp. was tested by nested PCR for the amplification of 16S-23S intergenic spacer. Multilocus sequence typing (MLST) was performed on B. miyamotoi isolates.
In total, 2407 ticks were collected (239 females, 232 males and 1936 nymphs). Female and male I. ricinus ticks had identical infection rates (both 12.1%) for Borrelia spp., while nymphal pools showed a minimum infection rate (MIR) of 3.3%. Sequencing revealed four Borrelia species: B. afzelii, B. garinii, B. valaisiana and B. miyamotoi.
The prevalence of B. miyamotoi in I. ricinus ticks registered similar levels to other reports from Europe suggesting that this agent might be well established in the local tick population.
___________________
**Comment**
If four borrelia species were discovered in German ticks, it’s highly likely these same ticks are transmitting to humans. German patients are sunk if doctors are utilizing worthless CDC 2-tiered testing as it ONLY uses one strain, which isn’t even discussed in this paper (B. burgdorferi).
Borrelia afzelii, miyamotoi, and garinii ALL are pathogenic to humans.
This 2004 article shows they found valaisiana in the cerebrospinal fluid in a, “61-year-old man with a history of spastic paraparesis, which is strong clinical evidence of advanced neuroborreliosis.” They further state, “This report is the first of genetic detection of B. valaisiana in CSF, which indicates a probable association of this genospecies with disease in humans.” https://wwwnc.cdc.gov/eid/article/10/9/03-0439_article
Sixteen years later we still don’t know if valaisianna is pathogen to humans.